Compare ADMA Biologics Inc (ADMA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Okta, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Okta, Inc. trades at $151.7 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 11.8× ADMA Biologics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | OKTA | |
|---|---|---|
Market Cap | $2.22B | $26.13B |
Sector | Health | Technology |
52-Week High | $20.38 | $154.62 |
52-Week Low | $7.60 | $62.93 |
Enterprise Value | $2.29B | $23.95B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
